Table 3.
Adverse events and immunosuppression
| Study | Sample size | Adverse events | Immunosuppression | |||
|---|---|---|---|---|---|---|
| Tumor | Immune rejection | GID | Others | |||
| Schiess 2021 [102] | 20 | No | No | 4 patients (possibly related) | Phlebitis, hematoma, hypertension, nausea, headache, lymphocytosis | Not performed |
| Venkataramana 2012 [103] | 8 | No | No | No | No | Not performed |
| Boika 2020 [104] | 12 | NP | NP | NP | NP | Not performed |
| Storch 2012 [105] | 7 | No | No | NP | NP | NP |
| Brazzini 2010 [106] | 53 | No | No | No | No | Not performed |
| Madrazo 2019 [107] | 7 | No | No | No | No | Cyclosporine A for 40 days |
| Lige 2016 [108] | 21 | No | No | No | No | Not performed |
| Sinelnyk 2015 [109] | 32 | No | No | No | No | Not performed |
| Yin 2012 [110] | 12 | No | No | No | No | Not performed |
| Gross 2011 [111] | 35 | No | No | 1 patient | Disturbance in attention, hallucination | Not performed |
| Stover 2005 [112] | 6 | No | No | No | Hallucination | Not performed |
GID graft-induced dyskinesia, NP not provided